Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets
Identifieur interne : 001079 ( Main/Merge ); précédent : 001078; suivant : 001080
Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets
Auteurs : Anna-Karin Maltais [Suède] ; Koert J. Stittelaar [Pays-Bas] ; Edwin J. B. Veldhuis Kroeze [Pays-Bas] ; Geert Van Amerongen [Pays-Bas] ; Marcel L. Dijkshoorn [Pays-Bas] ; Gabriel P. Krestin [Pays-Bas] ; Jorma Hinkula [Suède] ; Hans Arwidsson [Suède] ; Alf Lindberg [Suède] ; Albert D. M. E. Osterhaus [Pays-Bas]Source :
- Vaccine [ 0264-410X ] ; 2014.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Vaccin.
English descriptors
- KwdEn :
Abstract
Influenza is a contagious respiratory disease caused by an influenza virus. Due to continuous antigenic drift of seasonal influenza viruses, influenza vaccines need to be adjusted before every influenza season. This allows annual vaccination with multivalent seasonal influenza vaccines, recommended especially for high-risk groups. There is a need for a seasonal influenza vaccine that induces broader and longer lasting protection upon easy administration. Endocine<TM> is a lipid-based mucosal adjuvant composed of endogenous lipids found ubiquitously in the human body. Intranasal administration of influenza antigens mixed with this adjuvant has been shown to induce local and systemic immunity as well as protective efficacy against homologous influenza virus challenge in mice. Here we used ferrets, an established animal model for human influenza virus infections, to further investigate the potential of Endocine<TM> as an adjuvant. Intranasal administration of inactivated pandemic H1N1 /California/2009 split antigen or whole virus antigen mixed with Endocine<TM> induced high levels of serum hemagglutination inhibition (HI) and virus neutralization (VN) antibody titers that were also cross reactive against distant swine viruses of the same subtype. HI and VN antibody titers were already demonstrated after a single nasal immunization. Upon intratracheal challenge with a homologous challenge virus (influenza virus H1N1/The Netherlands/602/2009) immunized ferrets were fully protected from virus replication in the lungs and largely protected against body weight loss, virus replication in the upper respiratory tract and pathological changes in the respiratory tract. Endocine<TM> formulated vaccines containing split antigen induced higher HI and VN antibody responses and better protection from body weight loss and virus shedding in the upper respiratory tract than the Endocine<TM> formulated vaccine containing whole virus antigen.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000103
- to stream PascalFrancis, to step Curation: 001D16
- to stream PascalFrancis, to step Checkpoint: 000078
Links to Exploration step
Pascal:14-0134138Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Intranasally administered Endocine<<sup>TM</sup>> formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets</title><author><name sortKey="Maltais, Anna Karin" sort="Maltais, Anna Karin" uniqKey="Maltais A" first="Anna-Karin" last="Maltais">Anna-Karin Maltais</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Eurocine Vaccines AB, Karolinska Institutet Science Park</s1><s2>171 65 Solna</s2><s3>SWE</s3><sZ>1 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Suède</country><wicri:noRegion>171 65 Solna</wicri:noRegion></affiliation></author><author><name sortKey="Stittelaar, Koert J" sort="Stittelaar, Koert J" uniqKey="Stittelaar K" first="Koert J." last="Stittelaar">Koert J. Stittelaar</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Viroclinics Biosciences B.V.</s1><s2>3029 AK Rotterdam</s2><s3>NLD</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>Viroclinics Biosciences B.V.</wicri:noRegion></affiliation></author><author><name sortKey="Veldhuis Kroeze, Edwin J B" sort="Veldhuis Kroeze, Edwin J B" uniqKey="Veldhuis Kroeze E" first="Edwin J. B." last="Veldhuis Kroeze">Edwin J. B. Veldhuis Kroeze</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Viroclinics Biosciences B.V.</s1><s2>3029 AK Rotterdam</s2><s3>NLD</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>Viroclinics Biosciences B.V.</wicri:noRegion></affiliation></author><author><name sortKey="Van Amerongen, Geert" sort="Van Amerongen, Geert" uniqKey="Van Amerongen G" first="Geert" last="Van Amerongen">Geert Van Amerongen</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Viroclinics Biosciences B.V.</s1><s2>3029 AK Rotterdam</s2><s3>NLD</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>Viroclinics Biosciences B.V.</wicri:noRegion></affiliation></author><author><name sortKey="Dijkshoorn, Marcel L" sort="Dijkshoorn, Marcel L" uniqKey="Dijkshoorn M" first="Marcel L." last="Dijkshoorn">Marcel L. Dijkshoorn</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Radiology, Erasmus Medical Center</s1><s2>3000 DR Rotterdam</s2><s3>NLD</s3><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>3000 DR Rotterdam</wicri:noRegion></affiliation></author><author><name sortKey="Krestin, Gabriel P" sort="Krestin, Gabriel P" uniqKey="Krestin G" first="Gabriel P." last="Krestin">Gabriel P. Krestin</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Radiology, Erasmus Medical Center</s1><s2>3000 DR Rotterdam</s2><s3>NLD</s3><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>3000 DR Rotterdam</wicri:noRegion></affiliation></author><author><name sortKey="Hinkula, Jorma" sort="Hinkula, Jorma" uniqKey="Hinkula J" first="Jorma" last="Hinkula">Jorma Hinkula</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Eurocine Vaccines AB, Karolinska Institutet Science Park</s1><s2>171 65 Solna</s2><s3>SWE</s3><sZ>1 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Suède</country><wicri:noRegion>171 65 Solna</wicri:noRegion></affiliation></author><author><name sortKey="Arwidsson, Hans" sort="Arwidsson, Hans" uniqKey="Arwidsson H" first="Hans" last="Arwidsson">Hans Arwidsson</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Eurocine Vaccines AB, Karolinska Institutet Science Park</s1><s2>171 65 Solna</s2><s3>SWE</s3><sZ>1 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Suède</country><wicri:noRegion>171 65 Solna</wicri:noRegion></affiliation></author><author><name sortKey="Lindberg, Alf" sort="Lindberg, Alf" uniqKey="Lindberg A" first="Alf" last="Lindberg">Alf Lindberg</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Eurocine Vaccines AB, Karolinska Institutet Science Park</s1><s2>171 65 Solna</s2><s3>SWE</s3><sZ>1 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Suède</country><wicri:noRegion>171 65 Solna</wicri:noRegion></affiliation></author><author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E." last="Osterhaus">Albert D. M. E. Osterhaus</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Viroclinics Biosciences B.V.</s1><s2>3029 AK Rotterdam</s2><s3>NLD</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>Viroclinics Biosciences B.V.</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Viroscience, Erasmus Medical Center</s1><s2>3000 DR Rotterdam</s2><s3>NLD</s3><sZ>10 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>3000 DR Rotterdam</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0134138</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 14-0134138 INIST</idno><idno type="RBID">Pascal:14-0134138</idno><idno type="wicri:Area/PascalFrancis/Corpus">000103</idno><idno type="wicri:Area/PascalFrancis/Curation">001D16</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000078</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000078</idno><idno type="wicri:doubleKey">0264-410X:2014:Maltais A:intranasally:administered:endocine</idno><idno type="wicri:Area/Main/Merge">001079</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Intranasally administered Endocine<<sup>TM</sup>> formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets</title><author><name sortKey="Maltais, Anna Karin" sort="Maltais, Anna Karin" uniqKey="Maltais A" first="Anna-Karin" last="Maltais">Anna-Karin Maltais</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Eurocine Vaccines AB, Karolinska Institutet Science Park</s1><s2>171 65 Solna</s2><s3>SWE</s3><sZ>1 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Suède</country><wicri:noRegion>171 65 Solna</wicri:noRegion></affiliation></author><author><name sortKey="Stittelaar, Koert J" sort="Stittelaar, Koert J" uniqKey="Stittelaar K" first="Koert J." last="Stittelaar">Koert J. Stittelaar</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Viroclinics Biosciences B.V.</s1><s2>3029 AK Rotterdam</s2><s3>NLD</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>Viroclinics Biosciences B.V.</wicri:noRegion></affiliation></author><author><name sortKey="Veldhuis Kroeze, Edwin J B" sort="Veldhuis Kroeze, Edwin J B" uniqKey="Veldhuis Kroeze E" first="Edwin J. B." last="Veldhuis Kroeze">Edwin J. B. Veldhuis Kroeze</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Viroclinics Biosciences B.V.</s1><s2>3029 AK Rotterdam</s2><s3>NLD</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>Viroclinics Biosciences B.V.</wicri:noRegion></affiliation></author><author><name sortKey="Van Amerongen, Geert" sort="Van Amerongen, Geert" uniqKey="Van Amerongen G" first="Geert" last="Van Amerongen">Geert Van Amerongen</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Viroclinics Biosciences B.V.</s1><s2>3029 AK Rotterdam</s2><s3>NLD</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>Viroclinics Biosciences B.V.</wicri:noRegion></affiliation></author><author><name sortKey="Dijkshoorn, Marcel L" sort="Dijkshoorn, Marcel L" uniqKey="Dijkshoorn M" first="Marcel L." last="Dijkshoorn">Marcel L. Dijkshoorn</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Radiology, Erasmus Medical Center</s1><s2>3000 DR Rotterdam</s2><s3>NLD</s3><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>3000 DR Rotterdam</wicri:noRegion></affiliation></author><author><name sortKey="Krestin, Gabriel P" sort="Krestin, Gabriel P" uniqKey="Krestin G" first="Gabriel P." last="Krestin">Gabriel P. Krestin</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Radiology, Erasmus Medical Center</s1><s2>3000 DR Rotterdam</s2><s3>NLD</s3><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>3000 DR Rotterdam</wicri:noRegion></affiliation></author><author><name sortKey="Hinkula, Jorma" sort="Hinkula, Jorma" uniqKey="Hinkula J" first="Jorma" last="Hinkula">Jorma Hinkula</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Eurocine Vaccines AB, Karolinska Institutet Science Park</s1><s2>171 65 Solna</s2><s3>SWE</s3><sZ>1 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Suède</country><wicri:noRegion>171 65 Solna</wicri:noRegion></affiliation></author><author><name sortKey="Arwidsson, Hans" sort="Arwidsson, Hans" uniqKey="Arwidsson H" first="Hans" last="Arwidsson">Hans Arwidsson</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Eurocine Vaccines AB, Karolinska Institutet Science Park</s1><s2>171 65 Solna</s2><s3>SWE</s3><sZ>1 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Suède</country><wicri:noRegion>171 65 Solna</wicri:noRegion></affiliation></author><author><name sortKey="Lindberg, Alf" sort="Lindberg, Alf" uniqKey="Lindberg A" first="Alf" last="Lindberg">Alf Lindberg</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Eurocine Vaccines AB, Karolinska Institutet Science Park</s1><s2>171 65 Solna</s2><s3>SWE</s3><sZ>1 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Suède</country><wicri:noRegion>171 65 Solna</wicri:noRegion></affiliation></author><author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E." last="Osterhaus">Albert D. M. E. Osterhaus</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Viroclinics Biosciences B.V.</s1><s2>3029 AK Rotterdam</s2><s3>NLD</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>Viroclinics Biosciences B.V.</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Viroscience, Erasmus Medical Center</s1><s2>3000 DR Rotterdam</s2><s3>NLD</s3><sZ>10 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>3000 DR Rotterdam</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Ferret</term><term>Humoral immunity</term><term>Immune response</term><term>Immunological adjuvant</term><term>Influenza</term><term>Influenza A virus</term><term>Intranasal administration</term><term>Vaccine</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Virus grippal A</term><term>Voie intranasale</term><term>Vaccin</term><term>Immunité humorale</term><term>Réponse immune</term><term>Furet</term><term>Adjuvant immunologique</term><term>Grippe</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Influenza is a contagious respiratory disease caused by an influenza virus. Due to continuous antigenic drift of seasonal influenza viruses, influenza vaccines need to be adjusted before every influenza season. This allows annual vaccination with multivalent seasonal influenza vaccines, recommended especially for high-risk groups. There is a need for a seasonal influenza vaccine that induces broader and longer lasting protection upon easy administration. Endocine<<sup>TM</sup>> is a lipid-based mucosal adjuvant composed of endogenous lipids found ubiquitously in the human body. Intranasal administration of influenza antigens mixed with this adjuvant has been shown to induce local and systemic immunity as well as protective efficacy against homologous influenza virus challenge in mice. Here we used ferrets, an established animal model for human influenza virus infections, to further investigate the potential of Endocine<<sup>TM</sup>> as an adjuvant. Intranasal administration of inactivated pandemic H1N1 /California/2009 split antigen or whole virus antigen mixed with Endocine<<sup>TM</sup>> induced high levels of serum hemagglutination inhibition (HI) and virus neutralization (VN) antibody titers that were also cross reactive against distant swine viruses of the same subtype. HI and VN antibody titers were already demonstrated after a single nasal immunization. Upon intratracheal challenge with a homologous challenge virus (influenza virus H1N1/The Netherlands/602/2009) immunized ferrets were fully protected from virus replication in the lungs and largely protected against body weight loss, virus replication in the upper respiratory tract and pathological changes in the respiratory tract. Endocine<<sup>TM</sup>> formulated vaccines containing split antigen induced higher HI and VN antibody responses and better protection from body weight loss and virus shedding in the upper respiratory tract than the Endocine<<sup>TM</sup>> formulated vaccine containing whole virus antigen.</div></front></TEI><affiliations><list><country><li>Pays-Bas</li><li>Suède</li></country></list><tree><country name="Suède"><noRegion><name sortKey="Maltais, Anna Karin" sort="Maltais, Anna Karin" uniqKey="Maltais A" first="Anna-Karin" last="Maltais">Anna-Karin Maltais</name></noRegion><name sortKey="Arwidsson, Hans" sort="Arwidsson, Hans" uniqKey="Arwidsson H" first="Hans" last="Arwidsson">Hans Arwidsson</name><name sortKey="Hinkula, Jorma" sort="Hinkula, Jorma" uniqKey="Hinkula J" first="Jorma" last="Hinkula">Jorma Hinkula</name><name sortKey="Lindberg, Alf" sort="Lindberg, Alf" uniqKey="Lindberg A" first="Alf" last="Lindberg">Alf Lindberg</name></country><country name="Pays-Bas"><noRegion><name sortKey="Stittelaar, Koert J" sort="Stittelaar, Koert J" uniqKey="Stittelaar K" first="Koert J." last="Stittelaar">Koert J. Stittelaar</name></noRegion><name sortKey="Dijkshoorn, Marcel L" sort="Dijkshoorn, Marcel L" uniqKey="Dijkshoorn M" first="Marcel L." last="Dijkshoorn">Marcel L. Dijkshoorn</name><name sortKey="Krestin, Gabriel P" sort="Krestin, Gabriel P" uniqKey="Krestin G" first="Gabriel P." last="Krestin">Gabriel P. Krestin</name><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E." last="Osterhaus">Albert D. M. E. Osterhaus</name><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E." last="Osterhaus">Albert D. M. E. Osterhaus</name><name sortKey="Van Amerongen, Geert" sort="Van Amerongen, Geert" uniqKey="Van Amerongen G" first="Geert" last="Van Amerongen">Geert Van Amerongen</name><name sortKey="Veldhuis Kroeze, Edwin J B" sort="Veldhuis Kroeze, Edwin J B" uniqKey="Veldhuis Kroeze E" first="Edwin J. B." last="Veldhuis Kroeze">Edwin J. B. Veldhuis Kroeze</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001079 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 001079 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Main
|étape= Merge
|type= RBID
|clé= Pascal:14-0134138
|texte= Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets
}}
| This area was generated with Dilib version V0.6.34. |  |